HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
Kimball, A B, J M Sobell, C C Zouboulis, Y Gu, D A Williams, M Sundaram, H D Teixeira, and G B E Jemec. 2016. “HiSCR (Hidradenitis Suppurativa Clinical Response): A Novel Clinical Endpoint to Evaluate Therapeutic Outcomes in Patients With Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2 Adalimumab Study.”. Journal of the European Academy of Dermatology and Venereology : JEADV 30 (6): 989-94.